China’s ambitious global drive to provide developing countries with affordable COVID-19 vaccines suffered a major setback on Tuesday following new test results from Brazil that revealed Sinovac’s CoronaVac vaccine to be only 50% effective.
The findings from the Butantan Institute, a São Paulo-based public institute that is the first to complete late-stage trials of the CoronaVac vaccine, came as a big surprise because just last week the institute said Sinovac’s shot was 78% effective and offered total protection against severe cases of the disease.
…
- Get a daily email packed with the latest China-Africa news and analysis.
- Read exclusive insights on the key trends shaping China-Africa relations.
- Full access to the News Feed that provides daily updates on Chinese engagement in Africa and throughout the Global South.